Loading... Please wait... Loading... Please wait...
ESTIMATED
06/06/2024
06/06/2024
(AS OF MARCH 31)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.06 | -$0.06 | -$0.06 |
| Q2 2024 | 0 | -$0.10 | -$0.10 | -$0.10 |
| Q3 2024 | 0 | -$0.30 | -$0.30 | -$0.30 |
| Q4 2024 | 0 | -$0.15 | -$0.15 | -$0.15 |
| Q1 2025 | 0 | $0.02 | $0.02 | $0.02 |
| Q2 2025 | 0 | $0.11 | $0.11 | $0.11 |
| Q3 2025 | 0 | -$0.19 | -$0.19 | -$0.19 |
| Q4 2025 | 0 | $0.02 | $0.02 | $0.02 |
| Q1 2026 | 0 | $0.08 | $0.08 | $0.08 |
| Q2 2026 | 0 | $0.18 | $0.18 | $0.18 |
Lifecore Biomedical, Inc. last posted its earnings results on Thursday, June 6th, 2024. The company reported $-0.22 earnings per share for the quarter, topping analysts' consensus estimates of $-0.23 by $0.01. The company had revenue of 31.55 M for the quarter and had revenue of 103.27 M for the year. Lifecore Biomedical, Inc. has generated $-3 earnings per share over the last year ($-3.41 diluted earnings per share) and currently has a price-to-earnings ratio of -2.67. Lifecore Biomedical, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 29th, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 03/19/2024 | Q4 2023 | -$1.19 | $29.05 M | $31.55 M | 06/02/2023 | Q3 2023 | -$0.51 | $27.60 M | 03/16/2023 | Q2 2023 | -$0.23 | -$0.42 | -0.19 | $38.80 M | 03/16/2023 | Q1 2023 | -$0.23 | -$0.41 | -0.18 | $42.74 M | $43.36 M | 03/16/2023 | Q4 2022 | -$0.23 | -$1.24 | -1.01 | $47.63 M | 02/27/2022 | Q3 2022 | -$0.45 | $48.41 M | $53.07 M | 11/30/2021 | Q2 2022 | -$1.30 | $129.49 M | 08/31/2021 | Q1 2022 | -$0.32 | $128.79 M | 05/31/2021 | Q4 2021 | -$0.10 | $139.83 M | 02/27/2021 | Q3 2021 | -$0.19 | $135.46 M | $137.78 M | 11/30/2020 | Q2 2021 | -$0.47 | $130.90 M | 08/31/2020 | Q1 2021 | -$0.38 | $135.64 M | 05/31/2020 | Q4 2020 | -$0.52 | $156.13 M | 02/28/2020 | Q3 2020 | -$0.39 | $152.93 M | 11/30/2019 | Q2 2020 | -$0.23 | $142.59 M | 08/31/2019 | Q1 2020 | -$0.16 | $138.71 M | 05/31/2019 | Q4 2019 | -$0.01 | $152.78 M | 02/27/2019 | Q3 2019 | $0.03 | $156.47 M | $155.69 M | 11/30/2018 | Q2 2019 | -$0.02 | $124.91 M | 08/31/2018 | Q1 2019 | $0.01 | $124.67 M |
|---|
A. Lifecore Biomedical, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 29th, 2024 based off last year's report dates.
A. In the previous quarter, Lifecore Biomedical, Inc. (NASDAQ:LFCR) reported $-0.22 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.23 by $0.01.
A. The conference call for Lifecore Biomedical, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Lifecore Biomedical, Inc.'s latest earnings report can be read online.
A. Lifecore Biomedical, Inc. (NASDAQ:LFCR) has a recorded annual revenue of $103.27 M.
A. Lifecore Biomedical, Inc. (NASDAQ:LFCR) has a recorded net income of $103.27 M. Lifecore Biomedical, Inc. has generated $-3.41 earnings per share over the last four quarters.
A. Lifecore Biomedical, Inc. (NASDAQ:LFCR) has a price-to-earnings ratio of -2.67 and price/earnings-to-growth ratio is 0.02.
